Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy

Antiviral Therapy

Volumn 11, Issue 3, 2006, Pages 361-370

  Bard, Jean Marie ^a   Lassalle, Régis ^b,c   Copeau, Jacqueline ^b   Bach Ngohou, Kalyane ^a   Nazih Sanderson, Françoise ^a   Rémy, Gérard ^d   Reynes, Jacques ^e   Ecobichon, Jean Luc ^f   Savés, Marianne ^b,c   Raffi, François ^g  

^a UNIVERSITÉ DE NANTES   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e GUI DE CHAULIAC HOSPITAL   (France)

^f Faculté Xavier Bichat   (France)

^g HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL LIPASE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; GLUCOSE METABOLISM; HEALTH CENTER; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIPID METABOLISM; LIPODYSTROPHY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; APOLIPOPROTEINS E; CHOLESTEROL, HDL; FEMALE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPOPROTEINS; MALE; PROTEASE INHIBITORS; TRIGLYCERIDES;

EID: 33744774479     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099
2. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13:465-471
3. SaintMarc T, Partisani M, Poizot Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14:37-49
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58
5. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibibtors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43
6. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34:1396-1405
7. Pasternak R. Adult Treatment Panel II versus Adult Treatment Panel III: What has changed and why? Am J Cardiol 2002; 89 Suppl 5A:3C-7C
8. Bard JM, Charles MA, Juhan-Vague I, et al. Accumulation of triglycerides-rich lipoprotein in subjects with abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21:401-414
9. Onat A, Hergenc G, Sansoy V, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003; 168:81-89
10. Bonnet E, Ruidavest JB, Tuech J, et al. Apolipoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001; 86:296-302
11. Le Moing V, Thiébaut R, Chêne G, et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185:471-80
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: insulin resistance and cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419
13. Luc G, Fievet C, Arveiler D, et al. Apolipoproteins C-III and E in apo B- and non-apo B-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM Study. J Lipid Res 1996; 37:508-517
14. Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommandation of the adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31:1216-1224
15. National Cholesterol Education Program. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adults treatment panel II). Circulation 1994; 89:1333-1345
16. Olivieri O, Bassi A, Stranieri C et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 2003; 44:2374-2381
17. Brown WV, Baginski ML. Inhibition of lipoprotein lipase by an apolipoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972; 46:375-382
18. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest 1985; 75:384-390
19. Le NA, Gibson JC, Ginsberg HN. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res 1988; 29:669-677
20. Blum B. Dynamics of apolipoprotein E metabolism in humans. J Lipid Res 1982; 23:1308-1316
21. Eisenberg S, Olivecrona T. Very low density lipoprotein: fate of phospholipids, cholesterol and apolipoprotein C during lipolysis in vitro. J Lipid Res 1979; 20:614-623
22. Nestel PJ, Huff MW, Billington T, Fidge NH. Changes in the plasma lipoprotein distribution of apolipoprotein C-II, C-III1, C-III2 and apolipoprotein B after heparin-induced lipolysis. Biochym Biophys Acta 1982; 712:94-102
23. Gibson JC, Brown WV. Effect of lipoprotein lipase and hepatic triglyceride lipase activity on the distribution of apolipoprotein E among plasma lipoproteins. Athersoclerosis 1988; 75:45-55
24. Alaupovic P, McConathy WJ, Fesmire J, Tavella M, Bard JM. Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias. Clin Chem 1988; 34:B13-B27
25. Alaupovic P, Bard JM, Tavella M, Shafer D. Identification of apo B-containing lipoprotein families in NIDDM. Diabetes, 1992; 41 Suppl 2:18-25